Biomedical (3750.T) traded up 0.8 % during a 24 hours period ending at 09:24 PM Central Europe on Tuesday 27th. One Biomedical stock can currently be bought for about JPY 759 on popular exchanges. Current supply of Biomedical stocks is 8.9 mn. Biomedical has a current market capitalization of JPY 6.7 bn and approximately JPY 2.6 mn worth of Biomedical was traded on exchanges in the last 24 hours. Since last month end, Biomedical has traded -13.23 % down. Simple moving average of last 200 days is at JPY 822.77. The highest price of past 52 weeks was recorded at JPY 890 on 03/25/2026. 52 weeks low was at JPY 743 on 10/26/2026.

Here is how related stocks have performed in the past 24 hours:

  • Hamayuu (7682.T) traded up 0.4 % and now trades at JPY 3,705. Current market capitalisation for Hamayuu is JPY 8.1 bn. Hamayuu has a current price to earnings ratio of 951.09.

  • A&a Material (5391.T) traded down -0.14 % and now trades at JPY 1,456. A&a Material has a market capitalisation of JPY 8.1 bn. A&a Material has a current price to earnings ratio of 8.31.

  • Manac Chemical L (4360.T) traded down -0.7 % and now trades at JPY 990. Manac Chemical L has a market capitalisation of JPY 8.1 bn. Current price/earnings ratio for Manac Chemical L is 8.25.

  • Jtp (2488.T) traded flat 0 % and now trades at JPY 1,509. Jtp has a market capitalisation of JPY 8.1 bn. Current price/earnings ratio for Jtp is 23.58.

  • Okayamaken Freight Transport (9063.T) traded up 0.76 % and now trades at JPY 4,010. Okayamaken Freight Transport has a market capitalisation of JPY 8.1 bn. Okayamaken Freight Transport has a current price to earnings ratio of 2.57.

About Biomedical

Cytori Cell Research Institute Inc. is a biotechnology company that specializes in cellular therapeutics and regenerative medicine. The company, which was formerly known as CytoGenix, was founded in 2004 and has its main office located in Vancouver, Canada. Cytori’s mission is to develop innovative solutions for regenerative medicine and cellular therapeutics by focusing on the utilization of adult stem cells for various therapeutic applications. The company has a strong research and development team that is committed to advancing the field of regenerative medicine through groundbreaking discoveries and advancements in technology. Cytori’s work has contributed significantly to the development of new therapies for various diseases, including heart failure, neurological disorders, and cancer. The company is traded on the NASDAQ stock exchange and its ticker symbol is CYTX.